Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 1 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 
Sponsor –Investigators Jane E. Gros s, MD PhD and Jerry A. Nick, MD 
 
Clinical Research Protocol 
Healthcare-associated links in transmission of nontuberculous mycobacteria among 
patients with cystic fibrosis 
Protocol Number: HALT NTM 
Version Date: May 8, 2020 
Sponsor-Investigator: Jane E. Gross, MD PhD 
National Jewish Health 
 
Jerry A. Nick, MD 
National Jewish Health 
Funding Organization: Cystic  Fibrosis Foundation (CFF) 
Coordinating Center: National Jewish Health 
Denver, CO [ZIP_CODE] 
Telephone: (303) 398 – 1876 
Fax: (202) 270 – 2189 
 
Approval : 
 
 
Jane E. Gross, MD PhD Date 
 
 
Approval : 
 
 
Jerry A. Nick, MD Date 
 
 
The information in this document may not be disclosed unless federal or state law or regulations require such 
disclosure. Subject to the foregoing, this information may be disclosed on ly to those persons involved in the 
study who have a need to know, with the obligation not to further disseminate this information. These 
restrictions on disclosure will apply equally to all futu re oral or written information, supplied to you by [CONTACT_796333], which is designated as "privileged" or "confidential". 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 2 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098404] read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety of the study participants enrolled under my supervision and providing 
the Sponsor-Investigators with complete and timely information, as outlined in the protocol. It is 
understood that all information pert aining to the study will be held strictly confidential and that 
this confidentiality requirement applies to all stu dy staff at this site. Furthermore, on behalf of 
the study staff and myself, I agree to maintain th e procedures required to  carry out the study in 
accordance with accepted GCP principles and to  abide by [CONTACT_38114]. 
 
Protocol Number: HALT NTM 
 
Protocol Title: Healthcare-associated links in transmission of nontube rculous mycobacteria 
among patients with cystic  fibrosis (HALT NTM) 
 
Protocol Date: May 8, 2020 
 
 
 
 
Investigator Signature [CONTACT_796362] #: 
Site Name: 
[CONTACT_2761]: 
 
 
 
 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 3 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
TABLE OF CONTENTS 
1 BACKGROUND  ............................................................................................................................... ........... 11 
1.1 OVERVIEW  OF NON‐CLINICAL STUDIES ............................................................................................................................... ...............  12 
1.2 OVERVIEW  OF PRELIMINARY  STUDIES ............................................................................................................................... .................  13 
2. STUDY RATIONALE  ...............................................................................................................................  15 
2.1 RISK / BENEFIT ASSESSMENT  ............................................................................................................................... ...............................  18 
3 STUDY OBJECTIVES  ............................................................................................................................... .... 18 
3.1 PRIMARY OBJECTIVE ............................................................................................................................... .............................................  18 
3.2 SECONDARY  OBJECTIVES  ............................................................................................................................... ......................................  18 
4 STUDY DESIGN ............................................................................................................................... .......... 19 
4.1 STUDY OVERVIEW  ............................................................................................................................... .................................................  19 
5 CRITERIA  FOR EVALUATION  ......................................................................................................................  19 
5.1 PRIMARY ENDPOINT  ............................................................................................................................... .............................................  19 
5.2 SECONDARY  ENDPOINTS  ............................................................................................................................... .......................................  19 
6 PARTICIPANT  SELECTION  ..........................................................................................................................  20 
6.1 STUDY POPULATION  ............................................................................................................................... .............................................  20 
6.2 INCLUSION  CRITERIA ............................................................................................................................... .............................................  20 
6.3 EXCLUSION  CRITERIA ............................................................................................................................... ............................................  20 
6.4 STUDY SPECIFIC TOLERANCE  FOR INCLUSION /EXCLUSION  CRITERIA .................................................................................................  20 
6.5 SCREEN FAIL CRITERIA ............................................................................................................................... ..........................................  20 
7 CONCURRENT  MEDICATIONS  ....................................................................................................................  20 
7.1 ALLOWED MEDICATIONS  AND TREATMENTS  ............................................................................................................................... ....... 20 
7.2 PROHIBITED  MEDICATIONS  AND TREATMENTS  ............................................................................................................................... ... 20 
8 STUDY TREATMENTS  ............................................................................................................................... . 20 
9 STUDY PROCEDURES  AND GUIDELINES  .....................................................................................................  21 
9.1 CLINICAL ASSESSMENTS  ............................................................................................................................... ........................................  21 
9.2 CLINICAL LABORATORY  MEASUREMENTS  ............................................................................................................................... ............ 21 
9.3 RESEARCH LABORATORY  MEASUREMENTS  ............................................................................................................................... ......... 21 
10 EVALUATIONS  BY [CONTACT_16990] .............................................................................................................................  21 
11 ADVERSE  EXPERIENCE  REPORTING  AND DOCUMENTATION  ......................................................................  21 
12 DISCONTINUATION  AND REPLACEMENT  OF PARTICIPANTS  .......................................................................  22 
12.1 EARLY WITHDRAWAL  OF PARTICIPANTS  FROM THE STUDY ...............................................................................................................  22 
12.2 REPLACEMENT  OF PARTICIPANTS  ............................................................................................................................... .........................  22 
13 PROTOCOL  VIOLATIONS  ...........................................................................................................................  22 
14 DATA SAFETY MONITORING  .....................................................................................................................  22 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 4 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
 15 STATISTICAL  METHODS  AND CONSIDERATIONS  ........................................................................................  22 
15.1 GENERAL CONSIDERATIONS  ............................................................................................................................... .................................  22 
15.2 DEMOGRAPHIC  AND BASELINE CHARACTERISTICS  .............................................................................................................................  23 
15.3 ANALYSIS OF PRIMARY ENDPOINT  ............................................................................................................................... .......................  23 
15.4 ANALYSIS OF SECONDARY  ENDPOINTS....................................................................................................................... .........................  23 
15.5 INTERIM ANALYSIS ............................................................................................................................... ................................................  23 
15.6 SAMPLE SIZE ............................................................................................................................... .........................................................  24 
16 DATA COLLECTION,  RETENTION  AND CLINICAL MONITORING  ....................................................................  24 
16.1 DATA COLLECTION  INSTRUMENTS  ............................................................................................................................... .......................  24 
16.2 DATA MANAGEMENT  PROCEDURES  ............................................................................................................................... ....................  24 
16.3 SECURITY AND ARCHIVAL OF DATA ............................................................................................................................... ......................  25 
16.4 AVAILABILITY  AND RETENTION  OF INVESTIGATIONAL  RECORDS ........................................................................................................  25 
16.5 MONITORING  ............................................................................................................................... ........................................................  25 
16.6 PARTICIPANT  CONFIDENTIALITY  ............................................................................................................................... ...........................  25 
17 ADMINISTRATIVE,  ETHICAL, REGULATORY  CONSIDERATIONS  ...................................................................  25 
17.1 PROTOCOL  AMENDMENTS  ............................................................................................................................... ...................................  26 
17.2 INSTITUTIONAL  REVIEW BOARDS AND INDEPENDENT  ETHICS COMMITTEES  ....................................................................................  26 
17.3 INFORMED  CONSENT FORM ............................................................................................................................... .................................  26 
17.4 CONSENT FOR COLLECTION  AND USE OF CFF REGISTRY ID NUMBER ..............................................................................................  26 
17.5 PUBLICATIONS  ............................................................................................................................... .......................................................  27 
17.6 INVESTIGATOR  RESPONSIBILITIES  ............................................................................................................................... .........................  27 
18 REFERENCES  ............................................................................................................................... ..............  28 
APPENDIX  1: COLORADO ‐RESEARCH  DEVELOPMENT  PROGRAM  NTM ISOLATE RESULT LETTER ..........................  31 
APPENDIX  2. REDCAP USER GUIDE .....................................................................................................................34  
APPENDIX  3 ENVIRONMENTAL  SAMPLING  PROTOCOL  ......................................................................................  37 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 5 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098405] of 1996 
IP&C Infection prevention and control 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
MAC M. avium complex 
NTM Nontuberculous mycobacteria 
PI [INVESTIGATOR_796280] #: 1.0 Version Date: 2020_0508 Page 6 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
PROTOCOL SYNOPSIS 
 
TITLE Healthcare-associated links in transmission of nontuberculous 
mycobacteria among patients with cystic fibrosis (HALT NTM) 
SPONSOR- 
INVESTIGATOR Jane E. Gross, MD PhD 
Jerry A. Nick, MD 
FUNDING 
ORGANIZATION Cystic Fibrosis Foundation (CFF) 
NUMBER OF SITES Up to [ADDRESS_1098406] 
challenging infections to treat among CF patients, notable for 
prolonged treatment courses and of ten poor response to therapy. 
Positive cultures for NTM occur in about 20% of children and adults 
with CF. However, the source of NTM infection, modes of 
transmission, and exposure risks are poorly understood. It is thought 
that NTM is primarily acquired fr om environmental sites including 
soil and water as well as water supply systems to homes, hospi[INVESTIGATOR_600], and clinics and from aerosols gene rated by [CONTACT_796334], 
showers, and fountains. Nonetheles s, no direct molecular link has 
been established between environmental NTM and respi[INVESTIGATOR_796281]. Healthcare-associated tran smission of NTM among CF patients 
has been suspected and is of growing concern for CF Centers 
worldwide. Widespread global tran smission of NTM, potentially via 
person-to-person transmission of fomites and aerosols has been 
reported, but no standardized epi[INVESTIGATOR_796282]-associated NTM ac quisition has been published. 
STUDY DESIGN PART A / Epi[INVESTIGATOR_796283]: 
The CO-RDP provides a national re ference laboratory for CF NTM. 
NTM respi[INVESTIGATOR_796284] 
U.S. undergo culture, molecular identification, antimicrobial 
susceptibility, and whole genome sequencing (WGS). Using this approach, the CO-RDP has identified clusters of NTM isolates, 
defined as highly similar strains at the genomic level, harbored by [CONTACT_796335]. 
These identifications have height ened our concern for potential 
healthcare-associated NTM acquisiti on originating from patient-to- 
patient transmission or a comm on environmental source within 
Centers. Using integrated clinical and epid emiological research methods, the 
HALT NTM retrospective epi[INVESTIGATOR_796285](s) of care betw een patients with highly similar 
NTM isolates in a Center. The HALT NTM toolkit facilitates a 
stepwise process by [CONTACT_796336][INVESTIGATOR_796286]-RDP as part 
of an NTM cluster. HALT NTM is available to the entire CF 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 7 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 Foundation Care Network, under a collabo rative agreement, to initiate 
a standardized, independent, conf idential, internal NTM outbreak 
investigation. A control comparison group will also be investigated. 
 
PART B / Water Biofilm Collection : 
Clustered NTM isolates could orig inate from a shared healthcare 
water source. Biofilms from healthcare water supplies will be collected and NTM recovered, identified, and sequenced to determine if the respi[INVESTIGATOR_796287]. 
PARTICIPANT 
STUDY DURATION PART A/ Epi[INVESTIGATOR_796288]: 
CF Centers will be eligible for enrollment as NTM clusters are 
identified by [CONTACT_81938]-RDP. The total duration of the study and 
analysis is 3 years. 
 
PART B / Water Biofilm Collection: 
CF Centers will be eligible for enrollment as NTM clusters are identified by [CONTACT_81938]-RDP. The total duration of the study and 
analysis is 3 years. 
PRIMARY OBJECTIVE PART A / Epi[INVESTIGATOR_796289]: 
Our primary objective is to implem ent a standardized epi[INVESTIGATOR_796290], via the HALT NTM t ool kit, in CF Care Centers 
identified as having clusters of highly similar NTM isolates. We will assess the origins and prevalence of  healthcare associated patient to 
patient transmission of NTM among different CF Care Centers. We 
will characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting. 
 
PART B / Water Biofilm Collection: 
The primary objective is to determine if NTM strains identified in 
clusters are related to strains isol ated from water biofilm sources in 
the CF healthcare setting. Because hospi[INVESTIGATOR_796291] a risk to CF patients, we aim to perform WGS of 
NTM isolates from healthcare biof ilms obtained from CF Centers 
with NTM clusters among patients to determine if the biofilm isolates 
are highly related to the isol ates recovered from patients. 
SECONDARY 
OBJECTIVES PART A / Epi[INVESTIGATOR_796283]: 
The secondary objectives are to: 
 Assess degree of proximity of subj ects in time and/or space. 
 Compare the relationship between similarity of strains and 
degree of proximity of subjects. 
 Model the relationship between the degree of similarity and 
strains with the proximity and subject characteristic variables. 
PART B / Water Biofilm Collection: 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 8 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 The secondary objectives are to: 
 Characterize clinically-relevant NTM isolates and healthcare 
biofilms. 
 Describe most common biofilm s ources within the healthcare 
setting harboring clinically  relevant NTM isolates. 
NUMBER OF 
PARTICIPANTS PART A / Epi[INVESTIGATOR_796283]: 
Unlimited and based on the number of patients identified in an NTM 
cluster within an individual CF Care Center (prospectively collected data). Two controls will be identified  for every subject within a cluster. 
 
PART B / Water Biofilm Collection: N/A 
PARTICIPANT 
SELECTION CRITERIA: 
Inclusion Criteria PART A / Epi[INVESTIGATOR_796288]: 
Inclusion Criteria: 
1. Written informed consent is not required for this retrospective 
epi[INVESTIGATOR_119262]. 
 2. Diagnosis of CF consistent  with the [ADDRESS_1098407] a history of NTM 
species or sub-species collected from expectorated sputum, 
induced sputum and/or bronchoalv eolar lavage and identified by 
[CONTACT_81938]-RDP as falling into a highly -related cluster within a single 
CF Care Center. 
 4. Controls subjects are male or fe male participants of any age who 
have a history of NTM species or sub-species collected from 
expectorated sputum, induced s putum and/or bronchoalveolar 
lavage and identified by [CONTACT_81938] -RDP as NOT falling into a 
highly-related cluster within a single CF Care Center. 
 
PART B / Water Biofilm Collection: 
 Inclusion Criteria: 
 N/A 
PARTICIPANT PART A / Epi[INVESTIGATOR_796288]: 
SELECTION 
CRITERIA: N/A 
Exclusion Criteria PART B / Water Biofilm Collection: 
 N/A 
CONCOMMITANT 
MEDICATIONS Allowed: N/A 
Prohibited: N/A 
PRIMARY PART A / Epi[INVESTIGATOR_796288]: 
ENDPOINT Identification of a shared healthcare-associated source(s) between 
 patients in a CF Care Center. 
 PART B / Water Biofilm Collection: 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 9 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 Identification of biofilm is olates that are highly related to the isolates 
recovered from patients. 
SECONDARY 
ENDPOINTS PART A / Epi[INVESTIGATOR_796288]: 
The secondary endpoints are: 
 Incidence and prevalence of CF NTM species/subspecies by 
[CONTACT_101820]. 
 
PART B/ Water Biofilm Collection: 
The secondary endpoints are: 
 Incidence and prevalence of healthcare-associated water 
biofilm NTM species/subspecies by [CONTACT_101820]. 
EXPLORATORY 
EVALUATIONS None 
PLANNED INTERIM 
ANALYSIS No formal interim analysis involving a data monitoring committee 
(DMC) is planned. 
STATISTICS 
PRIMARY 
ANALYSIS PLAN PART A / Epi[INVESTIGATOR_796288]: 
For the primary endpoint, biostatistica l analysis of the multicenter data 
will be completed using both qualitative and quantitative approaches. We will identify a set of variables used to assess degree of proximity of subjects in time and/or space.  For example, two subjects with 
neighboring rooms at a hospi[INVESTIGATOR_796292], but proximity would be increased for tw o subjects at a f acility that had 
longer overlap time, relative to a pair of subjects that had shorter overlap. We will explore creating co mposite measures of quantitative 
proximity that incorporate multiple variables. Qualitative measures of proximity, such as location type (t esting laboratory, patient room) will 
also be assessed. Several testing appr oaches will  be used to compare 
the relationship between similarity of strains and degree of proximity 
of subjects. In the simplest form, de scriptive statistics will be computed 
for proximity variables, for pairs of  subjects who are determined to 
have similar strains versus those who have dissimilar strains, and 
multivariate or 2-sample t-tests will be performed to test for differences between these groups. More advanced modeling will be performed to determine the relationship between the degree of similarity in strains with the proximity and subject characteristic variables; multiple linear regression will be used when considering continuous strain similarity, while multiple logistic regression will be used when considering subjects with dichotomized (sim ilar/dissimilar) strains to other 
subjects. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 10 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 PART B / Water Biofilm Collection: 
Several testing approaches will be used to compare the relationship 
between similarity of strains between the clustered patients and environmental isolates. Descriptive statistics will be computed for 
proximity variables, fo r pairs of subjects and environmental isolates 
that are determined to have sim ilar strains versus those who have 
dissimilar strains, and multivariate or 2-sample t-tests will be performed to test for differences between these groups. 
RATIONALE FOR 
NUMBER OF 
PARTICIPANTS The CO-RDP provides a national refe rence laboratory for CF NTM. 
NTM respi[INVESTIGATOR_796293] 
U.S. undergo culture, molecular identification, antimicrobial 
susceptibility, and WGS. Using this approach, the CO-RDP has identified clusters of NTM isolates, defined as highly similar strains at 
the genomic level, harbored by [CONTACT_796337]. All CF Centers, found to have clusters 
of highly-related NTM is olates will be offered enrollment. Subject 
enrollment is unlimited and based on the number of patients identified  
in an  NTM  cluster  within an  individual  CF  Care Center 
(prospectively collected data). 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 11 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 
1 BACKGROUND 
Healthcare-associated transmission of NTM Pulmonary nontuberculous mycobacteria (NTM) infe ction is recognized as one of the most 
challenging infections to treat am ong cystic fibrosis (CF) patien ts, notable for prolonged treatment 
courses and often poor response to therapy.
1,2 Positive cultures for NTM occur in  about 20% of 
children and adults with CF.[ADDRESS_1098408] igation tool for healthcare-associated 
NTM acquisition has been published. 
CO-RDP serves as a national reference laboratory for CF NTM 
The Colorado Research Development Program (CO- RDP) provides a national reference laboratory 
for CF NTM.12 NTM respi[INVESTIGATOR_796284] 
U.S. undergo culture, molecular identification, antimicrobial susceptibility, and whole genome 
sequencing (WGS).[ADDRESS_1098409] ers of NTM within the care center network 
Analysis of the 2016 CF Foundation (CFF) Patient  Registry Annual Data Report found 20% of 
patients cultured for NTM between 2012-[ADDRESS_1098410] once.17 In 2017, 
of the 15,041 CF patients in the national registry  who had an NTM culture performed that year, 
1,903 (12.7%) had an NTM species isolated one or more times.18 The modes of acquisition of NTM 
in CF remain unclear ( Figure 1 ). 
The CO-RDP comprises multiple coordinated 
cores which receive, bank, culture, sequence, and analyze NTM clinical isolates from CF clinics 
around the U.S. Extracted NTM DNA from 
received samples is sequenced via WGS and analyzed for phylogenetic  relatedness. As of 
January 2019, [ADDRESS_1098411] been sequenced. Phylogenetic data of NTM isolates 
from CF patients in the U.S. ( Figure 2 ), as well  as 
reference and environmental stains worldwide, are being collected in an ongoing fashion by [CONTACT_81938]-
RDP, and we found that highly similar NTM 
strains are shared within  individual Care Centers 
(Figure 3 ) as well as between geographically 
 
 
Figure 1 : Possible modes of NTM 
transmission. 
 
 
  
 
  
 
 
 
 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 12 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
distant Centers. This work is clinically significant 
because a shared highly si milar strain within a 
healthcare setting suggests common environmental 
sources of acquisition or  patient- to-patient 
transmission.9 
To define relatedness, the CO-RDP has examined 
the range of single-nucl eotide polymorphism 
(SNP) differences among isolates from different 
patients compared to longitudinal isolates from the same patients over time to establish an evidence-
based SNP threshold that is consistent with a clonal 
or highly similar strain within each NTM 
species.
13,19 As this genomic database expands, 
thresholds of similarity will be refined through continued acquisition of longitudinal isolates 
collected from patients. Together, the inter- and 
intra-patient information defines a threshold to initiate an epi[INVESTIGATOR_53069] c investigation. As the 
number of SNPs between strains increases, the 
likelihood of shared or igin decreases. SNP 
threshold numbers are also dependent on the size 
of the core genome used to assess similarity. The 
CO-RDP utilizes WGS and phylogenomic analysis to examine the population structure and diversity 
of each NTM species and subspecies, and to 
identify clustered strain s that are phylogenetically-
related and nearly identi cal at the core genome 
level. Using the CO-RDP data driven 
methodology, a threshold of 15 SNP for M. 
abscessus ssp. abscessus (MAB) is stringent, 
reliable and provides an optimal approach  to assess similarity between isolates.
13,[ADDRESS_1098412] for NTM isolate comparison and was used in the study at Papworth Hospi[INVESTIGATOR_796294].9 The authors examined WGS on 168 consecutive 
isolates of M. abscessus from 31 adult CF patients in a Cent er from 2007-2011. Using core genome 
SNP analysis, they identified highly similar (<25 SNP) clusters of M. abscessus massiliense 
(MMAS) isolates from patients who demonstr ated opportunities for cross- infection via 
overlappi[INVESTIGATOR_796295]. The authors 
concluded substantial evid ence existed to support healthcare-acquired transmission . One smaller 
study utilized a similar approach to evaluate hi ghly similar NTM isolates, but the data did not 
support healthcare-associated transmission of infection.21 
 
 
1.1 Overview of Non-Clinical Studies 
Not Applicable  
M. abscessus  subsp. abscessus  
M. avium 
M. abscessus  subsp. massiliense  
M. intracellulare  
M. chimaera  
M. spp. (unknown)  
M. abscessus  subsp. bolletii 
M. chelonae 
M. asiaticum  
M. kubicae 
M. arupense  
Figure 2 : CF NTM isolates sequenced by [CONTACT_702656]-RDP. 
 
 
 
Figure 3 : CO-RDP identified NTM clusters 
within 10 CF Care Centers. 

Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 13 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098413] been sequenced from 79 U.S. Care 
Centers, representing a total of 13 predominant NTM species and subspecies (Figure 2 ). To 
determine a threshold of genetic similarity for hi ghly similar isolates, pair wise SNP distances in 
the core genome were calculated between all pa irs of “same” (within- patient) or “different” 
(between-patient) isolates. We obs erved that 25 or fewer SNPs define background similarity of 
same-patient isolates for MAB and MMAS . Thus, a conservative threshold of 15 SNPs was chosen 
to define genetic clusters between patients, re presenting likely transmission events or shared 
source acquisition. 
 
Findings : Unpublished data from the CO-RDP of 114 is olates from CF MAB patients across the 
country demonstrates 26 of 114 (23%) had isolates in highly related clusters. Twelve of 114 (11%) 
had isolates in clusters and received care in  the same Center. Clusters are occurring among 
multiple M. abscessus subspecies as well as Mycobacterium avium complex (MAC) subspecies . 
 
Preliminary results from one Care Center utilizin g the HALT NTM toolkit inve stigated six clusters 
of patients with highly similar re spi[INVESTIGATOR_796296], including M. abscessus and MAC. The 
size of the highly related clusters ranged from 2-3 patients. Among the six identified NTM clusters, 
two clusters occurred wi th MAB, one with MMAS , two with M. avium (MAV) , and one with M. 
intracellulare. No patients within a cluster are related or liv ing together. This is the first description 
of a MAC cluster. 
 
Cluster [ADDRESS_1098414] period with MAV+ culture. Subject B was defined as the pa tient with the second 
longest period with MAV+ culture. Subject C was defined as the patient with the shortest period 
with MAV+ culture. Subjects in Cluster 1 were compared using the following pair comparison: 
AB, AC, and BC. The abstraction timeframe for Pair AB was 67 months, Pair BC was 36 months, 
and Pair AC was 79 months. Results of the HA LT NTM toolkit revealed Subjects A and B had a 
1-day CF clinic overlap ( Figure 5 ). At that time, Subject A cultured positive for MAV, but Subject 
B did not. Local clinic IP&C standards at that ti me required patients to d on a mask when outside 
of a clinic room and required gown and gloving by [CONTACT_13922], but not ancill ary staff. Subjects A 
and B were seen by [CONTACT_796338]. Points of overlap during 
the clinic visit included: Subjects A and B had a clinic visit on the sa me afternoon, waited in a 
shared waiting room, underwent spi[INVESTIGATOR_582658]  a common access PFT laboratory room, and had a 
nutrition consult within the subjec t’s clinic room with the same  nutritionist. Subject B cultured 
positive for MAV [ADDRESS_1098415] culture d positive for MAV. Points of overlap included: 
Subjects B and C were seen by [CONTACT_796339] a shared waiting room , and spi[INVESTIGATOR_582658] a common access PFT laboratory room prior 
to being placed in their respective clinic room. Subject C first cultured positive for MAV [ADDRESS_1098416] period with MAB+ culture. Subject B had the shortest peri od with MAB+ culture. 
The abstraction timeframe for Pair AB was [ADDRESS_1098417] B 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 14 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
 
Figure 5 : Timeline of overlaps observed in Clusters 
1, 2, and 6.  
cultured positive for MAB [ADDRESS_1098418] A. Local 
hospi[INVESTIGATOR_796297]&C standards at that time required patie nts to don a mask when outside of a clinic room 
and required gown and gloving by [CONTACT_796340]’s  room. Subjects A and B were 
physically separated by [CONTACT_796341][INVESTIGATOR_39223]. At th at time, CF patients had privileges to walk 
unaccompanied through the hospi[INVESTIGATOR_796298] a mask and had access to a common 
coffeemaker (Keurig) and sink. 
 
Cluster [ADDRESS_1098419] 
day of the admission when overlap occurred. Points of overlap included: 
Subjects A and B both had spi[INVESTIGATOR_428692] a physical therapy consult on the same day during the admission overlap. 
Local hospi[INVESTIGATOR_796297]&C standards at that 
time required patients 
to don a mask when outside of a clinic room and required gown and gloving by [CONTACT_796342]’s room. CF patients had privileges to walk unaccompanied through the hospi[INVESTIGATOR_796299] a mask and had access to a common coffeemak er (Keurig) and sink. Subject B cultured 
positive for MAV [ADDRESS_1098420] AB hospi[INVESTIGATOR_796300] . There was no overlap 
among the Cluster 6 subjects in the clinic setting. The timeline of overlap for Clusters 1, 2, and 6 
are shown ( Figure 5 ). 
 
Four sets of paired control patients with MAB were also compared utilizing the HALT NTM 
toolkit. Control patients were iden tified as having isolates that we re determined to be unique and 
unrelated. In all 4 control patient pairs with unr elated strains no healthcare-associated points of 
overlap were identified. The abstraction timeframe  for the control pairs ranged from 4-7 years. 
 
Discussion: Martiniano et. al . evaluated the clinical significance of a first positive CF NTM culture 
and reported subjects that develop active NTM disease have a lower baseline forced expi[INVESTIGATOR_184849] 1 second (FEV 1) at the time of first positive culture and an increased rate of decline in 
FEV [ADDRESS_1098421] period of time with NTM+ culture. The timeframe ends when the second paired patient 
has a first positive culture. This approach to setting the timeline for data 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 15 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098422] involving the PFT laboratory an d/or a single nutritionist, not 
donning gown and gloves, in both Pairs AB as we ll as BC. Based on the most recent CF IP&C 
guidelines, a plausible bacter ial transmission event may occur with horizontal surface 
contamination of equipment such as in the PFT  laboratory and/or involve surface contamination 
of staff skin and clothing wh en not donning protective, remova ble gowns and gloves while caring 
for CF patients.[ADDRESS_1098423] occurred via droplets carried on the 
exposed skin or clothing of staff caring for multiple CF patients or by [CONTACT_796343] . In Cluster 2 , both subjects became MAB+ within [ADDRESS_1098424] IP&C measures with single patient room s, healthcare staff gown ing and gloving, patients 
wearing masks, aggressive cleaning procedures between patients, and maintenance of patient-to-
patient separation of [ADDRESS_1098425] healthcare-associated  NTM transmission continue to 
appear in the literature.8-10 A standardized approach to investigation of healthcare-associated 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 16 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098426] in stances of increased probability of transmission 
events. Understanding risk for NTM transmission in the setting of the cu rrent  IP&C guidelines 
has the potential to significantly decrease risk of health care-associated transmission events of 
NTM among people with CF . 
 
An overview of the HALT NTM investigation process is outlined ( Figure 4 ). NJH IRB approval 
for the HALT NTM toolkit is active. Currently th e CO-RDP receives CF NT M respi[INVESTIGATOR_796301]. Submitting physicians receive a 
letter acknowledging receipt of the sample; most  commonly informing them that the isolate is 
genetically unique. However, samples initially identif ied as unique may subsequently be identified 
as part of a cluster of highly similar isolates wh en additional strains are added to the database. We 
will continue to update the Care Centers on the st atus of their isolates periodically. When WGS 
related clusters are identified, we will determine if the patients receive care in the same CF Program. 
 
 
 
  
 
 
 
  
 
 
 
 
1) Related clusters are defined as WGS 
SNP distance ≤ 15 AND within a 
Care Center.  
2) Toolkit establishes directionality of 
possible infection transmission based on length of NTM colonization.
 
3) Example pairing of four subjects 
A,B,C,D, where A is the subject with 
the longest NTM colonization: Pair 
AB, AC, AD, BC, BD, CD.  
4) Consults include ENT, respi[INVESTIGATOR_432718], physical therapy, etc.  
 
Figure 4 : HALT NTM Study Flowchart. 
 
When highly similar isolates are identified within an  individual Care Center, a form letter entitled, 
CO-RDP NTM Isolate Results for CF Care Centers ( Appendix 1 ), will be sent to each affected 
institution. The letter informs the Centers of highly similar NTM isolates among two or more 
patients within their Center. The letter will also extend the invitation to participate in the HALT NTM study. To put the study in context, we will pr ovide a summary of clus ter data available to 
date, the goals and methods of this study, as we ll as IRB documents. The invitation to participate 
in HALT NTM will initiate a simple enrollment  process and recommend collaboration with the 
Center’s local IP&C team for investigation into a potential healthcare- associated transmission 
event. With enrollment, instructions will be provided on how to access the web-based HALT NTM 
investigation toolkit to facilita te a standardized healthcare-associated NTM investigation and a 
HALT NTM Toolkit User’s Guide will be provided ( Appendix 2 ). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 17 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
The primary function of the HALT NT M abstraction toolkit is to assess an occurrence of overlap 
between two or more patients identified in the clus ter within the CF healthcare setting, defined as 
CF clinic, hospi[INVESTIGATOR_796302]. An overl ap is defined as a healthcare setting where two 
or more CF patients identified in the cluster rece ived care in the same setting for any period of 
time within 24 hours . A point instance of overlap is define d as a specific physical room within 
the healthcare setting (clinic, hos pi[INVESTIGATOR_307], or research area) where tw o or more CF patients identified 
in the cluster received care. An example includes  the following: Subject [ADDRESS_1098427] 2 are both 
seen in clinic on 12/12/16. Subject 1 is in the clinic from 10:00-12: 00. Subject 2 is in  clinic from 
1:00-3:00. In this example, an overlap in clin ic is observed between Subject [ADDRESS_1098428] 1 performs spi[INVESTIGATOR_796303] 1 at 10:00 on 12/12/[ADDRESS_1098429] 
2 performs spi[INVESTIGATOR_796303] 1 at 2:00 on 12/12/16. In this example, a point 
instance overlap is observed in the PFT laboratory because two clustered patients were in Room [ADDRESS_1098430] an overlap, but a point instance of overlap may not be identified. 
In either case, data will be recorded accordingly. 
 
Testing for water biofilm sources in the CF  healthcare setting: NTM are known to colonize 
municipal water systems and have been identified in healthcare facilities.27-[ADDRESS_1098431] implicated inhala tion of aerosolized NTM 
via showerheads as a possible sour ce of acquisition of infection.33 A recent study demonstrated 
that showerheads receiving water from  municipal water treatment plants harbor clinically-
relevant NTM .34 On a more global level, Bryant et al. reported widespread dominant circulating 
NTM clones.11 This worldwide distributi on could be explained by [CONTACT_796344] . Further environmental evaluation of healthcare environments is essential to 
understanding healthcare- associated environmental risk factors in acquisition of NTM infection . 
 
Biofilms are the preferred samples for isolation of  NTM in water systems of all types because the 
hydrophobic NTM cells preferentially adhere to pi[INVESTIGATOR_796304], thus 
ensuring their persistence.  Average colony counts/cm2 of premise plumbing biofilm samples is 
between 1,000-15,000 CFU/cm2, whereas water (suspended) densities are between 10-100 
CFU/mL.35 Thus, the sensitivity of NTM detection is orders of magnitude higher for biofilm 
compared to water samples. With advanced molecular analys is and better understanding of 
previous NTM nosocomial outbreaks, the CO-RDP findings of highly relate d NTM clusters among 
CF patients within the same CF Care Centers raises concern for nosocomial 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 18 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
transmission . In order to better unde rstand risk for nosocomial NTM acquisition among CF 
patients with clonal NTM respi[INVESTIGATOR_796305], determining the relatedness of clustered CF NTM 
clinical respi[INVESTIGATOR_796306] . 
 
2.1 Risk / Benefit Assessment 
As a retrospective, epi[INVESTIGATOR_796307]. There 
is minimal risk to subjects in the study. 
 
3 STUDY OBJECTIVES 
 
3.1 Primary Objective 
PART A / Epi[INVESTIGATOR_796288]: 
The primary objective of the epi[INVESTIGATOR_796308] a 
stepwise process by [CONTACT_796345] e epi[INVESTIGATOR_796309]-RDP as part of an NTM cluster. 
 
PART B / Water Biofilm Collection: 
The primary objective of water biofilm collection is to determine of NTM strains identified in 
clusters are related to the strains isolated from wa ter biofilm sources in the CF healthcare setting. 
3.2 Secondary Objectives 
PART A / Epi[INVESTIGATOR_796288]: 
The secondary objectives are to: 
 Determine subject overlap: 
Frequency, location and source of overlap within  the healthcare system  within the 2-year 
abstraction timeframe. 
 Evaluate infection prevention and control (IP&C) measures: 
Use of single patient rooms, healthcare sta ff gowning and gloving, pati ents wearing masks, 
aggressive cleaning procedures between patient s, and maintenance of  patient-to- patient 
separation of 6 feet or more within  the 2-year abstraction timeframe. 
 
PART B / Water Biofilm Collection: 
The secondary objectives are to: 
 Culture healthcare-associated wa ter biofilm environmental NTM. 
 Evaluate effectiveness of a standardized NT M disease treatment protocol to serve as 
baseline/reference estimates of endpoints in cl inical care and future  therapeutic trials. 
 Support biomarker development for markers of  NTM treatment response through banking 
of clinical specimens and NTM is olates linked with outcomes data. 
 Characterize clinical features of patients achieving treatment success compared to those 
unresponsive to treatment. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 19 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
4 STUDY DESIGN 
 
4.1 Study Overview 
PART A / Epi[INVESTIGATOR_796288]: 
This study will retrospectively revi ew and collect data from patients with CF and culture positive 
for an NTM isolate falling in a highly-related clus ter, identified by [CONTACT_81938]-RDP, within a single 
CF Care Center. Two control subjects will be identified by [CONTACT_81938]-RDP for every subject falling 
within a cluster. Retros pective epi[INVESTIGATOR_796310] i nput into REDCap is detailed 
(Appendix 1 and 2) . Up to 20 Care Centers will be offered enrollment. 
 
PART B / Water Biofilm Collection : 
This study will also collect and analyze water bi ofilms from a variety of water sources in the 
healthcare setting including sink  faucets, showerheads, shower  hoses, ice machines, drinking 
fountains, and decorative water features. Envir onmental sampling instructions are detailed 
(Appendix 3) . 
 
5 CRITERIA FOR EVALUATION 
 
5.1 Primary Endpoint 
PART A / Epi[INVESTIGATOR_796288]: 
Identification of a shared healthcare-associated s ource(s) between patients in a Care Center with 
identical NTM isolates. 
 
PART B / Water Biofilm Collection: 
Identification of clinically-relevant NTM isolates  and prevalent environmental genotypes with in 
healthcare setting water biofilms. 
 
5.2 Secondary Endpoints 
PART A / Epi[INVESTIGATOR_796288]: 
The secondary endpoints are: 
 Adherence to CF IP&C guidelines. 
 Characterization of points of patient overlap. 
 
PART B / Water Biofilm Collection: 
The secondary endpoints are: 
 Incidence and prevalence of NTM species/subs pecies within healthcare water biofilms. 
 Determine if biofilm isolates are highly re lated to isolates reco vered from patients. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 20 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
6 PARTICIPANT SELECTION 
 
6.1 Study Population 
Participants with a diagnosis of CF who meet all of the inclusion and none of the exclusion criteria 
will be eligible for participation in this study. 
 
6.2 Inclusion Criteria 
PART A / Epi[INVESTIGATOR_796288]: 
1. Male or female participant of any age at enro llment Diagnosis of CF consistent with the 2017 
CFF Guidelines. 
2. NTM-positive for a species or sub-species in the 2 years prior to enrollment that has never 
been treated or current Denver si ngle-center stud y participant. 
 
PART B / Water Biofilm Collection: 
N/A 
 
6.3 Exclusion Criteria 
PART A / Epi[INVESTIGATOR_796288]: 
N/A 
 
PART B / Water Biofilm Collection: 
N/A 
 
6.4 Study Specific Tolerance for Inclusion/Exclusion Criteria 
N/A 
 
6.5 Screen Fail Criteria 
N/A 
 
7 CONCURRENT MEDICATIONS 
 
7.1 Allowed Medications and Treatments 
No available therapy for CF is restricted. 
 
7.2 Prohibited Medications and Treatments 
N/A 
 
8 STUDY TREATMENTS 
Part A (Epi[INVESTIGATOR_796311] n) is retrospective collection of epi[INVESTIGATOR_46294]. Part B 
(Water Biofilm Collection) is exclusively envi ronmental sampling and does not include subject 
involvement. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 21 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
9 STUDY PROCEDURES AND GUIDELINES 
REDCap data collection is deta iled (Appendix 1 and Appendix 2 - Epi[INVESTIGATOR_796288]). 
Environmental sampling instructi ons are detailed (Appendix 3). 
9.1 Clinical Assessments 
 
9.1.1 Demographics and CFF Registry ID 
Demographic information (date of birth, sex, ra ce, zip code) will be recorded. CFF Registry 
number will be recorded for pa rticipating CF participants. 
9.1.[ADDRESS_1098432] underwent or is undergoing treatment of CF NTM disease. 
 
9.1.6 Drug Toxicity Monitoring 
N/A 
 
9.2 Clinical Laboratory Measurements 
N/A 
 
9.3 Research Laboratory Measurements 
N/A 
 
10 EVALUATIONS BY [CONTACT_796346]. 
 
11 ADVERSE EXPERIENCE REPO RTING AND DOCUMENTATION 
Not applicable. Adverse Events an d Serious Adverse Experience wi ll not be reported for this 
retrospective study. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 22 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
12 DISCONTINUATION AND REPLACEMENT OF PARTICIPANTS 
 
12.1 Early Withdrawal of Participants from the Study 
N/A. 
 
12.2 Replacement of Participants 
N/A 
 
13 PROTOCOL VIOLATIONS 
A protocol violation occurs when the participant, investigator, or the Sponsor fails to adhere to 
significant protocol requirements affecting the eligibility criteria  and primary endpoint criteria. 
Failure to comply with Good Clinical Practice (G CP) guidelines may also result in a protocol 
violation. 
There will be no protocol violations. We will mon itor for protocol deviations. If deviations are 
identified, we will request modifications as  necessary to meet protocol guidelines. 
 
14 DATA SAFETY MONITORING 
N/A 
 
15 STATISTICAL METHODS AND CONSIDERATIONS 
 
15.1 General Considerations 
For each of the primary and secondary outcomes, bios tatistical analysis of the multicenter data will 
be completed using both qualitative and quantitativ e approaches. We will identify a set of variables 
used to assess degree of proximity of subjects in  time and/or space. For example, two subjects with 
neighboring rooms at a hospi[INVESTIGATOR_796292], but proximity would be increased for 
two subjects at a facility that had longer overlap time , relative to a pair of subjects that had shorter 
overlap. We will explore creating composite measures of quantitative proximity that incorporate multiple variables. Qualitative measures of proxim ity, such as  location type (testing laboratory, 
patient room) will also be assessed. Several testing approaches will be used to compare the relationship between similarity of strains and degree of proximity of subjects. In the simplest form, 
descriptive statistics will be computed for proxi mity variables, for pairs of subjects who are 
determined to have similar strains versus those who have dissimilar strain s, and multivariate or 2-
sample t-tests will be performed to test for differences between these groups. More advanced 
modeling will be performed to determine the rela tionship between the degree of similarity in 
strains with the proximity and subject characteristic variables; multiple linear regression will be used when considering continuous strain similarit y, while multiple logistic regression will be used 
when considering subjects with dichotomized (similar/dissimilar) strains to other subjects. 
 
15.1.1  Data Sets Analyzed 
All analyses will be based on the group of subjects  that are identified by [CONTACT_81938]-RDP as having 
NTM isolates, defined as highly si milar strains at the genomic le vel, harbored by [CONTACT_796347] a si ngle Care Center. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 23 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
15.2 Demographic and Baseli ne Characteristics 
The following baseline demographic and clinical char acteristics will be reported: age, gender, race, 
ethnicity, zip code, and NTM sub/species. 
15.3 Analysis of Primary Endpoint 
PART A / Epi[INVESTIGATOR_796288]: 
The primary endpoint will characterize the origins and prevalence of healthcare-associated patient-
to-patient transmission of NTM among different CF Care Centers. We will further characterize the source(s) of direct or indirect transmission of NTM within an indi vidual CF healthcare setting. We 
will identify a set of variables used to assess degree of proximity of subjects in time and/or space. For example, two subjects with neighboring room s at a hospi[INVESTIGATOR_796292], but 
proximity would be increased for two subjects at a facility that had longer overlap time, relative to 
a pair of subjects that had shorter overlap. We will explore creating composite measures of quantitative proximity that incorporate multiple vari ables. Qualitative measures of proximity, such 
as location type (testing laboratory, patient room) will also be assessed. Several testing approaches 
will be used to compare the relationship between similarity of strains and degree of proximity of subjects. In the simplest form, de scriptive statistics will be comput ed for proximity variables, for 
pairs of subjects who are determined to have si milar strains versus those who have dissimilar 
strains, and multivariate or 2-sample t-tests will be performed to test for differences between these 
groups. More advanced modeling will be performe d to determine the relationship between the 
degree of similarity in strains with the proximity and subject characteristic variables; multiple linear regression will be used when considering continuous strain sim ilarity, while multiple logistic 
regression will be used when considering subjects  with dichotomized (similar/dissimilar) strains 
to other subjects. 
PART B / Water Biofilm Collection: 
The primary endpoint will charac terize clinically-relevant NTM found in water biofilms within 
CF healthcare settings and determine if the biofilm isolates are highly related to isolates recovered from patients. 
15.4 Analysis of Secondary Endpoints 
PART A / Epi[INVESTIGATOR_796288]: 
The secondary endpoints will characterize CF Center  adherence to the CF IP&C guidelines as well 
as characterize points of patient overlap. Basic summaries of points of potential transmission 
overlap will be provided. 
 
PART B / Water Biofilm Collection: 
The incidence and prevalence of NTM species a nd subspecies within healthcare water biofilms 
will be characterized. Comparisons of NTM biofilm isolates and highly related patient isolates will be provided. 
 
15.5 Interim Analysis 
No formal interim analysis involving a data monitoring committee (DMC) is planned. However, 
annual reports summarizing key variables related to  site enrollment and adherence to protocol 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 24 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
will be generated. These reports will help guide prot ocol revisions. Details of the planned analysis 
for these annual reports can be found in the Statistical Analysis Plan (SAP). 
 
15.[ADDRESS_1098433] and CF Registry 
corresponding to a participant’s visit into the prot ocol-specific electronic REDCap database when 
the information corresponding to that visit is available. Participants will not be identified by [CONTACT_796348]  (or designee), but will be identified by a site 
number, participant number and initials. 
For all REDCap data colle ction, the time and date stamp trac ks the person entering or updating 
data and creates an electronic audit trail. 
The Investigator is responsible for all information collected on participants enrolled in this study. 
All data collected during the course of this study must be revi ewed and verified for completeness 
and accuracy by [CONTACT_737]. At the completion of the study, a copy of the REDCap data  will 
be provided to the site to be reta ined at the Investigator’s site. 
The data may be monitored by [CONTACT_796349]. 
 
16.[ADDRESS_1098434]. 
REDCap currently supports 240+ academic/non-pr ofit consortium partners on six continents and 
over 26,000 research end-users (www.project- redcap.org). 
Data Quality Control and Reporting 
After data have been entered into the study data base, data validation checks will be applied on a 
regular basis. As part of data  analysis, Matthew Stra nd, the lead biostatis tician on the study, will 
monitor for data outliers and will perform data cont rol. If data entry errors are encountered, the 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 25 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098435]. Data is  accessed based on  the individual’s role on the 
project. Logging and audit trails are maintained on all data interactions. All data is stored on a 
secure server, and backups are encrypted. Automatic  backup of the server s are performed  twice 
daily. 
 
16.[ADDRESS_1098436] make study data accessible to the monitor, other authorized  representatives 
of the Sponsor (or designee), IRB/IEC, and Regulatory Agency (e.g., FDA) inspectors upon 
request. Hard copy files will not be created. 
All study information will be maintained in REDCap  for a period of 5 years after database lock. 
There may be other circumstances for which the Spons or is required to main tain study records and, 
therefore, the Sponsor should be contact[CONTACT_123819]. 
 
16.5 Monitoring 
The study PIs and the CFF are authorized to m onitor the study. By [CONTACT_12570], the 
Investigator grants permission to  the Sponsor (or designee), and a ppropriate regulatory authorities 
to conduct on-site monitoring and/or auditing of all appropriate study documentation. Monitoring visits will be conducted by [CONTACT_111969] e Sponsor according to the U.S. CFR 21 Part 312 
and ICH Guidelines for GCP (E6) and to ensure  investigator compliance to 21 CFR Parts 50, 56 
and 312 and to GCP. 
 
16.6 Participant Confidentiality 
In order to maintain participant confidentialit y, only a site number, participant number and 
participant initials will identify all study participants in REDCa p. The participant’s CFF patient 
registry number will also be collected. Additiona l participant confidentiality issues (if applicable) 
are covered in the Clin ical Study Agreement. 
 
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS 
The study will be conducted according to the D eclaration of Helsinki, Protection of Human 
Volunteers (21 CFR 50), Institutional Review Boar ds (21 CFR 56), and Oblig ations of Clinical 
Investigators (21 CFR 312). 
To maintain confidentiality, all laboratory specime ns, evaluation forms, reports and other records 
will be identified by a coded number and initials only. Clinical information will not be released 
without written permission of the participant, except as necessary for monitoring by [CONTACT_1622]. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 26 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098437] icable privacy regulation s (e.g., Health Insurance 
Portability and Accountability Act of 1996, EU Data Protection Directive 95/46/EC). 
 
17.1 Protocol Amendments 
Any amendment to the protocol will be written by [CONTACT_1034]. Protocol amendments cannot be 
implemented without prior written IRB/IEC approva l except as necessary to eliminate immediate 
safety hazards to participants. A protocol amendment intended to eliminate an apparent immediate hazard to participants may be implemented immedi ately, provided the IRBs are notified within 5 
working days. 
 
17.2 Institutional Review Boards and Independent Ethics Committees 
The protocol and consent form will be reviewed and approved by [CONTACT_1201]/IEC of each participating 
center prior to study initia tion. Serious adverse experi ences regardless of causa lity will be reported 
to the IRB/IEC in accordance with the standard ope rating procedures and policies of the IRB/IEC, 
and the Investigator will keep the IRB/IEC informed as to the progress of the study. The Investigator will obtain assurance of IRB/IEC compliance with regulations. 
Any documents that the IRB/IEC may need to fulfill its responsibilities (such as protocol, protocol 
amendments, Investigator’s Brochure, consent forms, information concerning participant 
recruitment, payment or compensation procedures, or other pertinent information) will be submitted to the IRB/IEC. The IRB/IECs written unconditional approval of the study protocol and 
the informed consent form will be in the possession of the Investigator before the study is initiated. 
The IRB/IEC’s unconditional approval statement w ill be transmitted by [CONTACT_796350]. This approval must refer to 
the study by [CONTACT_256061]. 
Protocol and/or informed consent modifications or changes may not be initiated without prior 
written IRB/IEC approval except when necessa ry to eliminate immediate hazards to the 
participants or when the change (s) involves only logistical or ad ministrative aspects of the study. 
Such modifications will be submitted to the IRB/IE C and written verification that the modification 
was submitted and subsequently approved should be obtained. 
The IRB/IEC must be informed of revisions to other documents originally submitted for review; 
serious and/or unexpected adverse experiences o ccurring during the study in accordance with the 
standard operating procedures and policies of the IRB; new information that  may affect adversely 
the safety of the participants of the conduct of the st udy; an annual update an d/or request for re-
approval; and when the study has been completed. 
 
17.3 Informed Consent Form 
N/A 
 
17.4 Consent for Collection and Use of CFF Registry ID Number 
To facilitate possible future evaluation of retr ospective and prospective information from all 
participants in this study, the participant’s CFF Registry ID number will  be collected. The CFF 
registry collects data on all CF pa tients who consented to particip ate in the CFF registry and who 
are followed at CFF-accredited care centers. The regi stry data includes information from clinical 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 27 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098438] this number, the participant’s CF  registry number will be recorded in the CRF. 
 
17.[ADDRESS_1098439] of 1996. 
 
17.6 Investigator Responsibilities 
By [CONTACT_326821], the Investigator agrees to: 
1. Conduct the study in accordance with the protoc ol and only make changes after notifying the 
Sponsor (or designee), except when to protect th e safety, rights or we lfare of participants. 
2. Personally conduct or supervise the study (or investigation). 
3. Ensure that the requirements relating to obtaining informed consent and IRB review and 
approval meet federal guidelines, as st ated in § [ADDRESS_1098440] of the study are 
informed about their obligations in meeting the above commitments. 
5. Maintain adequate and accurate  records in accordan ce with §21 CFR 312.62 and to make those 
records available for inspection wi th the Sponsor (or designee). 
6. Ensure that an IRB that complies with the requir ements of §21 CFR part 56 will be responsible 
for initial and continuing review and approval of the clinical study. 
7. Promptly report to the IRB and the Sponsor (or designee) all ch anges in the research activity 
and all unanticipated problems involving risks to participants or others (to include amendments 
and IND safety reports). 
8. Seek IRB approval before any changes are made in the research study, except when necessary 
to eliminate hazards to the participants. 
9. Comply with all other requirement s regarding the obligat ions of clinical investigators and all 
other pertinent requirements listed in § 21 CFR part 312. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 28 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098441] ein TL. Shifting paradigms of nontuberculous 
mycobacteria in cystic fi brosis. Respir Res 2014;15:41. 
2. Floto RA, Olivier KN, Saiman L, et al. US Cy stic Fibrosis Foundation and European Cystic 
Fibrosis Society consensus recommendations  for the management of non-tuberculous 
mycobacteria in individuals with cyst ic fibrosis. Thorax 2016;[ADDRESS_1098442] 1:i1-22. 
3. Adjemian J, Olivier KN, Prevots DR. Ep idemiology of Pulmonary Nontuberculous 
Mycobacterial Sputum Positivity in Patients with  Cystic Fibrosis in the [LOCATION_002], 2010- 
2014. Ann Am Thorac Soc 2018;15:817-26. 
4. Primm TP, Lucero CA, Falkinham JO, 3rd. Health  impacts of environmental mycobacteria. 
Clin Microbiol Rev 2004;17:98-106. 
5. Falkinham JO, 3rd. Nontuberculous mycobacteria  from household plumbing of patients with 
nontuberculous mycobacteria disease.  Emerg Infect Dis 2011;17:419-24. 
6. Honda JR, Hasan NA, Davidson RM, et al. Envi ronmental Nontuberculous  Mycobacteria in 
the Hawaiian Islands. PLoS Negl Trop Dis 2016;10:e0005068. 
7. Prevots DR, Adjemian J, Fernandez AG, Know les MR, Olivier KN. Environmental risks for 
nontuberculous mycobacteria. Indivi dual exposures and climatic fact ors in the cystic fibrosis 
population. Ann Am Thorac Soc 2014;11:1032-8. 
8. Aitken ML, Limaye A, Pottinger P, et al. Re spi[INVESTIGATOR_796312] a lung transplant and cy stic fibrosis center. Am J Respir Crit Care 
Med 2012;185:231-2. 
9. Bryant JM, Grogono DM, Greaves D,  et al. Whole-genome sequencin g to identify transmission 
of Mycobacterium abscessus betwee n patients with cys tic fibrosis: a retros pective cohort study. 
Lancet 2013;381:1551-60. 
10. Johnston DI, Chisty Z, Gross JE, Park SY. Inve stigation of Mycobacterium abscessus outbreak 
among cystic fibrosis patients, Ha waii 2012. J Hosp Infect 2016;94:198-200. 
11. Bryant JM, Grogono DM, Rodrigu ez-Rincon D, et al. Emergen ce and spread of a human- 
transmissible multidrug-resistant nontuberc ulous mycobacterium. Science 2016;354:751-7. 
12. Colorado Cystic Fibrosis Research & Development Program. National Jewish Health. 
(Accessed Sept 2, 2018, at  https://www.nationaljewish.org/cocfrdp .) 
13. Epperson LE, Hasan NA, Davidson RM, et al. The Colorado Research and Development 
Program Molecular and Genomics Core: Surv eillance for Nontuberculous Mycobacteria 
Transmission or Shared Environmental Exposure in US Cystic Fibrosis Patients. Poster session 
presented at: The 31st Annual North American Cystic Fibrosis Conference; 2017 Nov 2-4; 
Indianapolis, IN. 
14. Healthcare-Associated Infection (HAI) Outbreak  Investigation Toolkit. Centers for Disease 
Control and Prevention, 2013. (Accessed Sept 2, 2018, at  
https://www.cdc.gov/hai/outbr eaks/outbreaktoolkit.html .) 
15. Lipner EM, Knox D, French J, Rudman J, Str ong M, Crooks JL. A Geospatial Epi[INVESTIGATOR_796313]: An Ecological Study in Colorado. Ann 
Am Thorac Soc 2017;14:1523-32. 
16. Lande L, Alexander DC, Wallace RJ Jr, Kwa it R, Iakhiaeva E, Williams M, et al. 
Mycobacterium avium in community and hous ehold water, suburban Philadelphia, 
Pennsylvania, [LOCATION_003], 2010-2012. Emerg Infect Dis 2019 Mar 14. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 29 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
17. Cystic Fibrosis Foundation Patient Registry 2016 Annual Data Report. Bethesda, MD: Cystic 
Fibrosis Foundation; 2017. 
18. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report. Bethesda, MD: Cystic 
Fibrosis Foundation; 2018. 
19. Hasan NA, Davidson RM, Epperson LE, et al. The Genomic Epi[INVESTIGATOR_796314]. Poster 
session presented at: The 31st Annual North American Cystic Fibrosis Conference; 2017 Nov 
2-4; Indianapolis, IN. 
20. Martiniano SL, Davidson RM, Nick JA. Nontube rculous mycobacteria in cystic fibrosis: 
Updates and the path forward. Pediatr Pulmonol 2017;52:S29-S36. 
21. Tortoli E, Kohl TA, Trovato A, et al. Mycobacter ium abscessus in patients with cystic fibrosis: 
low impact of inter-human transmission in Italy. Eur Respir J 2017;50. 
22. Adjemian J, Olivier KN, Seitz AE, Holland SM , Prevots DR. Prevalence of nontuberculous 
mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 
2012;185:881-6. 
23. Gross JE. Mycobacterium abscessus Epi[INVESTIGATOR_796315]. Poster session 
presented at: The 27th Annual North American Cystic Fibrosis Conference; [ADDRESS_1098443] 17-19; 
Salt Lake City, UT. 
24. Gross JE. Overcoming Barriers to Infection Control in Patients With Cystic Fibrosis. Oral 
presentation at: The 28th Annual North American Cystic Fibrosis Conference; [ADDRESS_1098444] 9- 11; 
Atlanta, GA. 
25. Gross JE. Healthcare-Associated Transmissi on of Nontuberculous mycobacteria Among 
Patients With Cystic Fibrosis. Oral presenta tion at: The 32nd Annual No rth American Cystic 
Fibrosis Conference; [ADDRESS_1098445] 18-20; Denver, CO. 
26. Saiman L, Siegel JD, LiPuma JJ, et al. Infec tion prevention and contro l guideline for cystic 
fibrosis: [ADDRESS_1098446] Control Hosp Epi[INVESTIGATOR_5541] 2014;[ADDRESS_1098447] 1:S1-S67. 
27. Williams MM, Armbruster CR, Arduino MJ. Plumbing of hospi[INVESTIGATOR_796316] a reservoir for 
opportunistically pathogenic microorgani sms: a review. Biofouling 2013;29:147-62. 
28. Shin JH, Lee EJ, Lee HR, et al. Prevalence of non-tuberculous mycoba cteria in a hospi[INVESTIGATOR_419196]. J Hosp Infect 2007;65:143-8. 
29. du Moulin GC, Stottmeier KD, Pelletier PA, Tsang AY, Hedley-Whyte J. Concentration of 
Mycobacterium avium by [CONTACT_2360][INVESTIGATOR_796317] t water systems. JAMA 1988;260:1599-601. 
30. Wallace RJ, Jr., Brown BA, Griff ith DE. Nosocomial outbreaks/ pseudo-outbreaks caused by 
[CONTACT_585379]. A nnu Rev Microbiol 1998;52:453-90. 
31. Olivier KN, Weber DJ, Wallace RJ, Jr., et al. Nontuberculous mycobacteria. I: multicenter 
prevalence study in cystic fibrosis. Am  J Respir Crit Care Med 2003;167:828-34. 
32. Baker AW, Lewis SS, Alexander BD, et al. Tw o-Phase Hospi[INVESTIGATOR_307]-Associated Outbreak of 
Mycobacterium abscessus: I nvestigation and Mitigation. Clin Infect Dis 2017;64:902-11. 
33. Thomson R, Tolson C, Carter R, Coulter C,  Huygens F, Hargreaves M. Isolation of 
nontuberculous mycobacteria (NTM) from house hold water and shower aerosols in patients 
with pulmonary disease caused by [CONTACT_110586] M. J Clin Microbiol 2013;51:3006-11. 
34. Gebert MJ, Delgado-Baquerizo M, Oliverio AM, et al. Ecological Analyses of Mycobacteria 
in Showerhead Biofilms and Their Rele vance to Human Health. MBio 2018;9. 
35. Falkinham JO, 3rd, Norton CD, LeChevallier  MW. Factors influencing numbers of 
Mycobacterium avium, Mycobacterium intracellu lare, and other Mycob acteria in drinking 
water distribution systems. Appl  Environ Microbiol 2001;67:1225-31. 
 
 
36. Martiniano SL, Sontag MK, Daley CL, Nick JA , Sagel SD. Clinical significance of a first 
positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014;11:36-44. 
   
 
APPENDIX [ADDRESS_1098448]. , 
 
The CF Foundation-funded Colorado Research and Deve lopment Program (RDP) is engaged in a nationwide 
study of the genetic characterizatio n of nontuberculous mycobacterium (N TM) across [LOCATION_002] CF Care 
Centers. We recently confirmed identifi cation of NTM isolates from the CF patients indicated below, who receive 
care in your CF center. We have genotyped these isolates by [CONTACT_796351] (clinical only, not for 
research), as well as whole genome sequencing, which pr ovided a genetic profile (DNA fingerprint), enabling us 
to determine similarity between strains. 
 
This analysis indicates that the patients listed below are infected with Mycobacterium abscessus ssp. abscessus 
and share a highly similar strain that  could be due to a shared environm ental exposure or possibly person-to- 
person transmission. 
 
Patient Name [CONTACT_796363]. If you are interest ed in conducting an independent, 
internal investigation for a shared he althcare-associated source (s) between two or more patients in your Center, 
please contact [CONTACT_796352], MD at [EMAIL_15136] to access the Healthcare-Associated Links in 
Transmission of Nontuberculous Myc obacteria in Patients with Cystic  Fibrosis (HALT NTM) toolkit. 
 
If you have questions about th is report please contact [CONTACT_162296], Adrah Levin, MPH, at 
[EMAIL_15137] or ([PHONE_16575]. You can also contact [CONTACT_796353], Jerry Nick, MD, at 
[EMAIL_15138] or at ([PHONE_16576]. If one of more of these patients are no longer under your care, or if 
you believe you have received this le tter in error, please contact [CONTACT_796354]. 
 
Sincerely, 
 
Charles L Daley, MD 
Director of RDP Culture and Biorepository Core 
Chief of Division of Mycobacterial and Respi[INVESTIGATOR_83078] 
[EMAIL_15139]  
 
 

 
Previously reported patients  sharing similar strains 
 
Mycobacterium abscessus, subsp. abscessus (reported 5/2018) 
Patient Name [CONTACT_796364], subsp. abscessus (reported 1/2019) 
Patient Name [CONTACT_796365]. massiliense (reported 1/2019) 
Patient Name [CONTACT_796366] (reported 1/2019) 
Patient Name [CONTACT_796367] (reported 1/2019) 
Patient Name [CONTACT_796368]. abscessus (reported 1/2019) 
Patient Name [CONTACT_796367] (reported 1/2019) 
Patient Name [CONTACT_796365]. abscessus (reported 9/2019) 
Patient Name [CONTACT_796369]. abscessus (reported 9/2019) 
Patient Name [CONTACT_796365]. abscessus (reported 9/2019) 
Patient Name [CONTACT_796368]. abscessus (reported 9/2019) 
Patient Name [CONTACT_796370] #: 1.0 Version Date: 2020_0508 Page 32 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
APPENDIX 2 REDCAP USER GUIDE 
So, you’ve received a letter from  National Jewish Health Advanced Diagnostic Laboratories 
(NJH ADx) saying you have patients  at your center with a highly  similar strain of NTM. Now 
what? 
1. Contact [INVESTIGATOR_124]. Gross at NJH. She will help you with initial questions regarding study 
design and study start-up, including IRB and database requirements. 
2. For NJH REDCap access, you will be sent a li nk to complete REDCap training. You will 
be asked the following: 
 For the question “Are you an employee of  National Jewish Health?” select No. 
 Explain your affiliation as “HALT NTM” 
 National Jewish Health S ponsor is “Jane Gross” 
 For department, indicate your CF center/institution name. 
 Complete the rest as indicated. 
 Email [CONTACT_137060] or Katie once you’ve been given access so you can be added to 
the project. 
3. Now you have access to the database. Log on to REDCap. On the welcome screen, open 
the HALT NTM project. 
4. On the left hand side under Applications, open the File Repository. Download the HALT 
NTM cheat sheet. 
5. Print a HALT NTM cheat sheet for each unique pair: 
 If there are two patients listed on you r letter, you will have one unique pair. 
 If there are three patients listed on your letter, you will have three unique pairs. 
 If there are four patients listed on your letter, you will have six unique pairs. 
 This is because the date ranges are comp ared between two subjects and is unique 
for each pair. 
6. Complete the first six lines on the HALT NTM cheat sheet for each unique pair. You 
will need to refer to it during pairing and data extraction. 
7. Back in REDCap, on the left hand side under Data Collection, click Add / Edit Records. 
On the Add/Edit Records page, click on the but ton Add new record. You will be taken to 
the Record Home Page. There will be a NEW Study ID XXX-XX . Record that number 
(XXX-XX ) on the HALT NTM cheat sheet . It is auto-generated by [CONTACT_61604]. You will 
need it later. 
8. The first Form to complete is Demographics. Open the form by [CONTACT_796355]. Near the top of the form under the header Pairs Survey is a link to 
the “ Finding Pairs survey .” Click on the link. You will be taken to an interactive tool 
that will help you determine if this subject is  “subject 1” or “subject 2” in this pairing. 
9. Using the letter from NJH ADx and the HA LT NTM cheat sheet, answer the questions. 
This will give you the pair number and subject number for the patients. Record those 
numbers on the HALT NTM cheat sheet. You ma y also choose to click Submit and then 
Download to get a printout of your survey responses for your record. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 33 of 35 
Protocol Template: © CFFT TDN Effective: [ADDRESS_1098449] & Exit Form button. 
11. Repeat Steps 6-[ADDRESS_1098450] or from Add/Edit Records listed under Data Collection on the 
left hand side. 
13. Using the HALT NTM cheat sheet, answer “For this pairing, is this Subject [ADDRESS_1098451] 
2?” Depending on your answer, you will be  asked to enter a date for the OTHER 
PATIENT in this pairing. Be sure to read the questions carefully a nd enter the correct 
date. 
14. Once the date has been entered, a box w ill pop-up with the Extraction Date Range. 
Record this on the HALT NTM cheat sheet. 
15. Now for the digging. In order to see if your  pair of patients had any overlap, you will 
need to enter dates for Inpatient hospi[INVESTIGATOR_36651], Outpatient Clinic visits, and Research 
Unit visits. Only record visits that fall within the Extraction Date Range. 
16. Keep digging! You’ve completed the extracti on for the first subject in the pair. Now 
repeat Steps 12-[ADDRESS_1098452] completed the Compare Form (all the date extractions) for a pair of 
subjects, you are ready to see if there is a ny overlap between these two patients. Click on 
“Compare Dates” on the left side under Proj ect Bookmarks. You will be asked to enter 
the internal record id ( XXX-XX) for the two subjects in the pair you are comparing. 
18. Take a deep breath and click “Compare s ubjects.” The program will let you know if 
there is any overlap in dates for Inpatient, C linic, and/or Research Visits. If there is, 
REDCap will mark those forms as red circles on the Record Status Dashboard. If there 
is no overlap, the circles will stay gr ey and you are done with this pair. 
19. However, if you have red circles on the Record Status Dashboar d, it is time to dig again. 
Clicking on a red circle will take you to an Overlap Form – there is one form for each 
location the program found date overlaps. The top of the form is uneditable, but you are 
able to see the Patient Name, Pair Number , Subject Number, and Date Range for the 
detailed data extraction. Use this informati on to complete the ques tions as best you can 
for each visit overlap ( red circle ). The more accurate you are able to be, the better the 
analysis can be. 
20. Once done, change status to “Complete,” a nd click “Save & Exit”. The status color 
changes to green on the Record Status Dashboard. You are done. 
 
 
Feel free to contact [CONTACT_796356]. Gross for he lp along with way or if you have any comments on 
this user guide or the REDCap project. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 34 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
Katie Poch 
[EMAIL_15140] 
[PHONE_16577] 
 
[CONTACT_796371] [EMAIL_15141] 
[PHONE_16578] 
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐[ADDRESS_1098453] each sampling site using a 
Google Maps on iPhone or Android. For more information:  
https://www.wikihow.com/Get ‐Latitude‐and‐Longitude ‐from‐Google‐Maps 
 
Record GPS similar to the following  and out to more than 5 significant  digits: 
NJ GPS LOCATION:  39°44'23.2"N  104°56'33.6"W  
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
2  
  
SINK FAUCET SAMPLING  
This protocol can be applied to sample water biofilms from kitchen, bathroom,  or outdoor sink 
faucets. 
BEFORE SAMPLING:  
1. Faucet should be as dry as possible 
2. Avoid sampling a faucet if it has been recently used or is wet 
3. If faucet is wet, DO NOT dry off. If possible, return to faucet at another time 
SAMPLING  
1. Identify the sink faucet and take a pi[INVESTIGATOR_796318]. 
2. Obtain one of the sterile dual‐tipped Flock swabs. 
3. Identify the point of the sink faucet where water 
exits . This is where the sample should be taken. 
Note: Depending  on the faucet, there might 
be a metal mesh on the faucet head similar 
the image to the right (“Step 4 under view”). If 
so, sample the mesh. 
Note: Depending  on the faucet, there might 
be an open pi[INVESTIGATOR_796319]. If so, sample up into the pi[INVESTIGATOR_5836]. 
4. Carefully open a new swab package. To do so, 
carefully pry open the swab package. Remove the swab by [CONTACT_796357]‐sterile surfaces; keep the swab sterile! Be careful not to 
touch anywhere  along the swab and only handle the swab by [CONTACT_796358]. 
5. If mesh sampling ‐ Firmly and thoroughly  swab the point on the sink faucet where water 
exits in a back and forth motion 10 times as well as a circular motion ‐ imagine that you are 
using the swab to “clean” the surface as completely  as possible. Twist the swab over and 
sample the same surface 10 more times to ensure this side of the swab has also collected 
biofilms. Avoid moving your hand onto the white applicator  stick. 
OR 
If open pi[INVESTIGATOR_796320] – Insert the swab into the pi[INVESTIGATOR_796321] a 
circular, firm stirring motion ‐ similar to stirring your coffee – [ADDRESS_1098454] the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., bathroom  
sink mesh or hospi[INVESTIGATOR_796322]). 
8. Place labeled tubes in a ziploc bag and refrigerate  samples until processing.  

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐[ADDRESS_1098455] SAMPLING  
1. Locate a dusty area at the sampling site – sample similar sites in all rooms of NJH and SJH. 
2. Before sampling,  take a representative  pi[INVESTIGATOR_796323]. 
3. Obtain one of the sterile dual‐tipped Flock swabs. 
4. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by [CONTACT_796359]‐ 
sterile surfaces; keep the swab sterile! Be careful not to touch anywhere  along the swab 
and only handle the swab by [CONTACT_796360]. 
5. Swab across the dusty surface using a back and forth motion [ADDRESS_1098456] as possible (refer to the 
image below). It often helps to rotate the tip of the swab as you brush it across the surface 
to make sure all sides of the swab get coated with visible dust. 
6. Once you have collected the sample, twist and remove the cap from the sterile collection  
tube that remains in the swab package and CAREFULLY  place the soiled dust swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., dust). 
8. Place labeled tubes in a ziploc bag and refrigerate  samples until processing.  
 

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
4  
  
SAMPLING  SHOWER HOSES AND SHOWERHEADS  
 
HOW TO SAMPLE THE HOSE (if it has a removable  showerhead):  
1. Take a representative  pi[INVESTIGATOR_796324] 
2. Carefully twist and remove the showerhead  from the 
shower hose at the connection  point labeled “1” on the 
image to the left. Do not place the showerhead  or hose 
down ; keep holding both in one of your hands. 
3. Obtain two of the sterile dual‐tipped Flock swabs. 
4. Carefully open a new swab package. To do so, carefully 
pry open the swab package. Remove the swab by [CONTACT_796361]‐ 
sterile surfaces; keep swab sterile! Be careful not to touch 
anywhere  along the swab and only handle the swab by [CONTACT_796360]. 
5. Firmly and thoroughly,  swab the inner portion of the hose at point “2” as shown on the 
image above. Using a “stirring” motion move the swab in and around the hose opening ‐ 
imagining  that you are using the swab to clean the surface or motion similar to stirring your 
coffee. Rotate the swab as you swirl to ensure all portions of the swabs have been exposed 
to biofilms. Rotate and swab [ADDRESS_1098457] 
the soiled swab into the transport  tube, being careful not to touch the swab tips with your 
fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., 
showerhead  (SHB) hose). 
8. Place labeled tubes in a ziploc bag and refrigerate  swab until processing.  
 
HOW TO SAMPLE THE SHOWERHEAD  FACE: 
1. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by [CONTACT_796359]‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by [CONTACT_796360]. 
2. Firmly and thoroughly,  swab the face of the showerhead  (the side from which the water 
would emerge) at point “3” as shown on the image above. Move the swab back and forth 
and around the entire surface of the showerhead  face 10 times in a circular motion ‐ 
imagining  that you are using the swab to clean the surface as completely  as possible. Don’t 
forget to get into the grooves on the showerhead  face. Twist the swab over and sample the 

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐[ADDRESS_1098458] the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
5. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information  ‐ the date, your initials, sample ID, and sample type (i.e., 
showerhead  biofilm (SHB)). 
6. Place labeled tubes in a ziploc bag and refrigerate  swab until processing.  
 
HOW TO SAMPLE A NON‐REMOVABLE  SHOWERHEAD:  
 
Locate the showerhead  in your home that is most often used. Swabbing  should be done when 
then showerhead  is as dry as possible — do not use a showerhead  that has been recently used 
or is wet. 
 
1. Locate the non‐removeable  showerhead.  Take a representative  pi[INVESTIGATOR_796325]. 
2. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by [CONTACT_796359]‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab 
and only handle the swab by [CONTACT_796360]. 
3. Firmly and thoroughly,  swab the OUTSIDE SURFACE  of the showerhead  (the side from 
which the water would emerge) using a firm back and forth as well as a circular motion, 
imagining  that you are using the swab to clean the showerhead  surface as completely  as 
possible. Don’t forget to get into the grooves on the showerhead  face. Twist the swab 
over and sample the same surface [ADDRESS_1098459] the soiled swab 
into the transport  tube, being careful not to touch the swab tips with your fingers. 
5. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a 
minimum  the following  information  ‐ the date, your initials, sample ID, and sample type 
(outside SHB). 
6. Place labeled tubes in a ziploc bag and refrigerate  swab until processing.  
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
6  
 
 
 
 
ICE MACHINE  SAMPLING  
 
1. Locate the ice machine. Take a representative  pi[INVESTIGATOR_796326]. Be sure to capture both the ice and water spouts. 
2. Obtain one of the sterile dual‐tipped Flock swabs. 
3. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by [CONTACT_796359]‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by [CONTACT_796360]. 
4. Insert the swab up into the plastic ice dispensing  “shoot” – highlighted  in red in the image 
below. 
5. Firmly and thoroughly,  swab all sides of the plastic ice 
shoot using a “stirring” motion to move the swab in 
and around the opening ‐ imagine that you are using 
the swab to methodically  clean the surface. Rotate 
the swab as you swirl to ensure all portions of the 
swab has been exposed to biofilms. Rotate and swab 
[ADDRESS_1098460] swab into the transport  tube, being careful not to 
touch the swab tips with your fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐ 
prepared  label that contains at a minimum  the 
following  information:  the date, your initials, sample ID, and sample type (i.e., ice machine).  
8. Repeat steps 2‐[ADDRESS_1098461] labeled tubes in a ziploc bag and refrigerate  swabs until processing.  

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
7  
  
DRINKING  FOUNTAIN  SAMPLING  
 
Sampling should be done when the spi[INVESTIGATOR_796327]—avoid  sampling a spi[INVESTIGATOR_796328]. If spi[INVESTIGATOR_796329], DO NOT dry off. If possible, return to faucet at 
another time. 
 
1. Locate the drinking fountain. Take a representative  pi[INVESTIGATOR_796330]. 
2. Obtain one of the sterile dual‐tipped Flock swab. 
3. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by [CONTACT_796359]‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by [CONTACT_796360]. 
 
 
4. If mesh sampling ‐ Firmly and thoroughly  swab the point on the spi[INVESTIGATOR_796331] 
a back and forth motion 10 times as well as a circular motion ‐ imagine that you are using 
the swab to “clean” the surface as completely  as possible. Twist the swab over and sample 
the same surface 10 more times to ensure this side of the swab has also collected biofilms. 
Avoid moving your hand onto the white applicator  stick. 
OR 
If open pi[INVESTIGATOR_796320] – Insert the swab into the pi[INVESTIGATOR_796321] a 
circular, firm stirring motion ‐ similar to stirring your coffee – [ADDRESS_1098462] the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
6. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., left 
drinking fountain).  
7. Place labeled tubes in a ziploc bag and refrigerate  samples until processing.  

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
8  
  
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
9  
  
WATER FEATURE SAMPLING  
 
1. Locate the water feature. It may be a fountain, pool, or water wall. Take a representative  
pi[INVESTIGATOR_796332]. 
2. Obtain one of the sterile dual‐tipped Flock swabs. 
3. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by [CONTACT_796359]‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by [CONTACT_796360]. 
4. Sample the dry “scumline”  (see image of a pool below) – located at the air‐water interface.  
Rotate the swab around as you sample the dry area right above the water line (see image of 
a pool below) and ensure all portions of the swab has been exposed to the biofilm. Rotate 
and swab [ADDRESS_1098463] the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
6. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., water 
feature). 
7. Place labeled tubes in a ziploc bag and refrigerate  swabs until processing.  
 
